Search Results

You are looking at 191 - 200 of 2,704 items for :

  • Refine by Access: All x
Clear All
Full access

Surgical Management of Vulvar Cancer

Thanh H. Dellinger, Amy A. Hakim, Stephen J. Lee, Mark T. Wakabayashi, Robert J. Morgan, and Ernest S. Han

participation. To participate in this journal CE activity: 1) review the educational content; 2) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/80141 ; and 3) view/print certificate. Release

Full access

Point: Hyperthermia with Radiation for Chest Wall Recurrences

Ellen L. Jones, Lawrence B. Marks, and Leonard R. Prosnitz

GC Hornsleth SN . ESHO quality assurance guidelines for regional hyperthermia . Int J Hyperthermia 1998 ; 14 : 125 – 133 . 30. Wahl AO Rademaker A Kiel KD . A multi-institutional review of chest well and breast re-irradiation for

Full access

Management of Anticoagulants in the Periprocedural Period for Patients With Cancer

Anita Pudusseri and Alex C. Spyropoulos

increased risk of bleeding. 4 Rates of periprocedural VTE and major bleeding are significantly higher in patients with cancer, 5 presenting a complex problem for clinicians in terms of periprocedural anticoagulation management. This article reviews the

Full access

Quantitative Imaging Assessment for Clinical Trials in Oncology

Katherine E. Hersberger, Mishal Mendiratta-Lala, Rocky Fischer, Ravi K. Kaza, Isaac R. Francis, Mirabella S. Olszewski, John F. Harju, Wei Shi, Frank J. Manion, Mahmoud M. Al-Hawary, and Vaibhav Sahai

that in “a randomized controlled trial…clinical trial primary endpoint image readers will be blinded to a subject’s treatment assignment because knowing the assignment would be presumed to create bias.” 20 This blinded independent central review (BICR

Full access

Liver-Directed Therapies in Patients With Advanced Neuroendocrine Tumors

Natalie B. Jones, Manisha H. Shah, and Mark Bloomston

of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at www

Full access

Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Abraham S. Kanate, Miguel-Angel Perales, and Mehdi Hamadani

across transplant centers. Notably, nearly 90% of transplant centers in the United States are reviewed and accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), thus establishing minimum standards for medical and laboratory

Full access

Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma

Pooja Ghatalia and Elizabeth R. Plimack

metastatic UC. Additionally, early data from clinical trials combining chemotherapy with immunotherapy in the frontline setting are also now available. This article reviews the data that led to FDA approval of these agents for mUC in patients who are

Full access

Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors

Sujata Narayanan and Pamela L. Kunz

journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/59437 ; and 4) view

Full access

Distress Screening and the Integration of Psychosocial Care Into Routine Oncologic Care

Jimmie C. Holland

York, New York, and Chair of the Distress Management Panel of NCCN in her presentation at the NCCN 18th Annual Conference. After exploring the emergence of psycho-oncology as a subspecialty, Dr. Holland reviewed the early role played by NCCN in

Full access

Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond

Jae Park

discussed strategies that may improve the efficacy of these approaches. Dr. Park also reviewed evidence‐based treatment approaches for adults with R/R B‐cell ALL. Blinatumomab The effectiveness of blinatumomab, a bispecific T-cell engager antibody designed